ArticleExperimental and therapeutic medicine2014
Rab25 expression predicts poor prognosis in clear cell renal cell carcinoma.
Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.Signal transduction and targeted therapy · 2023Review
- The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia.Small GTPases · 2020Review
- ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition.Epigenetics & chromatin · 2018Article
- Fifteen-gene expression based model predicts the survival of clear cell renal cell carcinoma.Medicine · 2018Article
- Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma.Scientific reports · 2017Article
- Rab25 GTPase: Functional roles in cancer.Oncotarget · 2017Review
- RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25.Cancer science · 2017Article
- High Rab25 expression associates with Ki67/TP53/CD133/VEGFR expression predicts poor prognosis in gastric cancer.International journal of clinical and experimental pathology · 2017Article
- High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy.Cancer cell international · 2017Article
- Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rab25 has been implicated in a number of types of cancer. However, its expression status and clinical implications in clear cell renal cell carcinoma (ccRCC) remain to be investigated. The purpose of this study was to investigate the significance of Rab25 status in patients with ccRCC. Rab25 expression was determined by western blot analysis in 30 fresh ccRCC samples. Immunohistochemistry was performed on the ccRCC samples and paired adjacent noncancerous tissues from 107 patients with ccRCC who had undergone surgery. The prognostic role and correlations with other clinicopathological factors were evaluated. Rab25 expression was upregulated in ccRCC tissues compared with that in paired adjacent noncancerous tissues. A high expression of Rab25 protein was significantly correlated with the primary tumor stage; lymph node metastasis; distant metastasis; tumor, node and metastasis stage and histological grade. A Kaplan-Meier survival analysis by log-rank test demonstrated that elevated Rab25 expression predicted lower overall survival time in patients with ccRCC. Notably, multivariate analyses revealed that expression of Rab25 was an independent prognostic factor in ccRCC (hazard ratio, 3.43; 95% confidence interval, 1.13-10.38; P=0.023). In conclusion, Rab25 is a potential prognostic biomarker in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.